Navigation Links
New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation
Date:11/14/2011

d providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2010, Boehringer Ingelheim posted net sales of about 12.6 billion euro while spending almost 24% of net sales in its largest business segment Prescription Medicines on research and development.

For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.

(1) Ferreira, J., et al. "Dabigatran Compared With Warfarin In Patients With Atrial Fibrillation And Symptomatic Heart Failure: A Subgroup Analysis Of the RE-LY Trial." AHA 2011 abstract.

(2) NHLBI website. "What Is Heart Failure?" Available at: http://www.nhlbi.nih.gov/health/health-topics/topics/hf/. Accessed on Oct. 31, 2011.

(3) Dries, D.L., et al. "Atrial Fibrillation Is Associated With an Increased Risk for Mortality and Heart Failure Progression in Patients With Asymptomatic and Sympotomatic Left Ventricular Systolic Dysfunction: A Retrospective Analysis of the SOLVD Trials." Journal of the American College of Cardiology. 1998; 32:695-703.  

(4) Fuster, V., et al. "ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation – Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation):  Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society." Circulation. 2006; 1
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
2. Clinilabs will Conduct Phase 1 Trial Using QTinno®
3. Bright Light into the Ear Canal Treats Seasonal Depression Effectively in Two Clinical Trials Presented by Valkee and University of Oulu
4. Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011
5. Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer
6. NeuroCog Trials Appoints Industry Executive Michael Hufford, Ph.D. to Chief Operating Officer
7. Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer
8. Jennerex to Present Final Survival Data From Randomized Phase 2 Clinical Trial of JX-594 in Advanced Liver Cancer at American Association for the Study of Liver Diseases Annual Meeting
9. Data From REMEDEE Trial Featuring OrbusNeichs Combo™ Dual Therapy Stent to be Presented in Late Breaking Clinical Trials and First Report Investigations Session at TCT 2011
10. Conatus Pharmaceuticals Terminates Phase 2 Clinical Trial of CTS-1027
11. CTRI Confirms Leading Indian CRO Supports Majority of Hemophilia Trials in India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Md. (PRWEB) January 22, 2015 ... its new UV-1280 multipurpose UV-visible spectrophotometer. Offering wavelength ... high-quality instrument is ideal for applications in a ... life science. , The user-friendly UV-1280 enables intuitive ...
(Date:1/22/2015)... Bedford, NH (PRWEB) January 22, 2015 ... offers a table top laboratory homogenizer, the PandaPLUS 2000, ... nanoparticles, nanodispersions, nanoemulsions , and cell disruption . ... processing dairy products, fruit juices, liquid food, food additives ...
(Date:1/22/2015)... Mass (PRWEB) January 21, 2015 Cambridge Semantics, ... Web technology, today announced that 2014 was a record-breaking year ... the capabilities of the Anzo Smart Data Platform and our ... and utilize insights from diverse data which led to record ...
(Date:1/22/2015)... Johnston, RI (PRWEB) January 22, 2015 ... State , The growing team of brand-neutral, independent consultants, ... CIO Philip Rogers explained that over the years, his ... including , Moroso, Town of Plainfield, as well as ...
Breaking Biology Technology:Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Cambridge Semantics Announces Record Results for 2014 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2
... 21, 2010 The Pharmaceuticals practice,at MarketsandMarkets is pleased to announce a ... , , ... Calorie/Diet Beverages Market (2010,-2015)Market Report. Early buyers will receive 10% customization of reports, ... ...
... ... today announced an agreement under which Therapure will provide manufacturing ... Israel with an executive management team based in Woburn, MA. Under ... clinical manufacturing for one of ProChon’s products, which may be used ...
... Minnesota-led researchers has cleared a major hurdle in the drive ... as high as current levels, which rarely exceed 30 percent. ... from semiconductors in solar cells can be captured and transferred ... for solar cell researchers seeking to build cheaper, more efficient ...
Cached Biology Technology:World Low Calorie/Diet Beverages Market (2010 -2015): MarketsandMarkets 2World Low Calorie/Diet Beverages Market (2010 -2015): MarketsandMarkets 3Therapure Biopharma Inc. Signs Biomanufacturing Contract with ProChon Biotech Ltd. 2University of Minnesota researchers clear major hurdle in road to high-efficiency solar cells 2
(Date:1/22/2015)... WINSTON-SALEM, N.C. , Jan. 16, 2015  A man-made ... working memory and other mental capabilities in adults with ... a pilot study led by researchers at Wake Forest ... 60 adults diagnosed with amnesic mild cognitive impairment (MCI) ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... of the "Global Wearable Technologies Market and ... Overview, Trends and Forecast 2014-2020" report to ... are smart devices that can be worn on ...
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... the "The Global Watermarking and Fingerprinting Markets" ... http://photos.prnewswire.com/prnh/20130307/600769 This insight ... watermarking and fingerprinting markets. Watermarking aims to control ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2The Global Watermarking and Fingerprinting Markets 2
... at UC Santa Barbara have discovered a caste of ... fluke species that invades the California horn snail. The ... the Proceedings of the Royal Society B . ... killer morphs defending the colony," said Armand M. Kuris, ...
... Menachem Shoham, PhD, associate professor and researcher in ... University School of Medicine, has identified new anti-pathogenic drugs ... Aureus (MRSA) harmless by preventing the production of toxins ... a growing public health problem causing 20,000 deaths per ...
... the support of an $11.8 million, five-year federal grant, ... are developing a quick-dissolving vaginal film containing a powerful ... they plan to begin testing it locally within a ... deliver breath fresheners, could have several advantages over vaginal ...
Cached Biology News:'Warrior worms' discovered in snails; UCSB scientists see possible biomedical applications 2Case Western Reserve researcher discovers new 'anti-pathogenic' drugs to treat MRSA 2Pitt gets $11.8 million to develop microbicide films for HIV prevention 2